ArticleCancers2026
Risk Factors for Mediastinal Lymph-Node Metastasis in Siewert Type I/II Esophagogastric Junction Cancers.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCurrently, a definitive diagnostic strategy for predicting mediastinal lymph-node (MLN) metastasis remains poorly established in Siewert Type I and II esophagogastric junction adenocarcinoma (EGJAC). This study aimed to evaluate long-term survival and identify objective, reliable preoperative risk factors for MLN metastasis to optimize perioperative treatment and surgical approach.
methodsWe retrospectively reviewed a well-defined cohort of 133 patients with Siewert Type I (33.1%) and II (66.9%) EGJAC who underwent R0 resection and complete follow-up at our institution between 2005 and 2025. Preoperative risk factors for histological MLN metastasis were evaluated using receiver operating characteristic (ROC) curve analysis and univariate/multivariate logistic regression models.
resultsThorough upper, middle, and lower MLND were completed in 57.9%, 72.9%, and 94.7% of patients, respectively. Pathological MLN metastasis was confirmed in 31.6% of patients and was significantly associated with poor overall and recurrence-free survival. ROC analysis demonstrated that an MLN short-axis diameter of ≥5 mm on CT, esophageal involvement length (EIL) in upper GI series ≥ 30 mm, and EIL in endoscopy ≥ 60 mm predict histological MLN metastasis. In univariate analysis, Siewert Type I, EIL in upper GI series ≥30 mm, EIL in endoscopy ≥ 60 mm, clinical tumor depth ≥ cT3, and CT node size ≥ 5 mm were correlated with MLN metastasis. Multivariate logistic regression analysis revealed that a clinical tumor depth of ≥cT3, EIL in upper GI series ≥ 30 mm, and a CT node size of ≥5 mm were independent predictors of MLN metastasis.
conclusionsClinical tumor depth, EIL, and size of MLN are powerful independent preoperative risk factors for MLN metastasis in Siewert Type I/II EGJAC. Utilizing these objective indices may help identify high-risk patients requiring intensive perioperative multidisciplinary strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.